Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Genmab A/S Dkk (GNMSF)

Genmab A/S Dkk (GNMSF)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]

Fundamentals

See More
  • Market Capitalization, $K 14,805,598
  • Shares Outstanding, K 61,690
  • Annual Sales, $ 804,360 K
  • Annual Income, $ 324,680 K
  • 60-Month Beta 0.26
  • Price/Sales 18.48
  • Price/Cash Flow 43.02
  • Price/Book 7.06
  • Price/Earnings ttm 47.82
  • Earnings Per Share ttm 5.04
  • Most Recent Earnings N/A on N/A
  • Next Earnings Date 02/19/20
  • Annual Dividend & Yield 0.00 (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sectors:

Price Performance

See More
Period Period Low Period High Performance
1-Month
229.0000 +1.53%
on 01/31/20
250.1500 -7.06%
on 02/21/20
+12.0500 (+5.47%)
since 01/27/20
3-Month
211.1500 +10.11%
on 01/06/20
250.1500 -7.06%
on 02/21/20
-2.9000 (-1.23%)
since 11/27/19
52-Week
160.8000 +44.59%
on 05/13/19
250.1500 -7.06%
on 02/21/20
+62.6000 (+36.85%)
since 02/27/19

Most Recent Stories

More News
Why Earnings Season Could Be Great for Genmab (GNMSF)

Genmab (GNMSF) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

GNMSF : 232.5000 (-3.13%)
Global Blood (GBT) Reports Narrower-Than-Expected Loss in Q1

Global Blood (GBT) reports narrower-than-expected loss in the first quarter of 2019.

GNMSF : 232.5000 (-3.13%)
GBT : 61.15 (-6.24%)
GILD : 72.66 (-2.73%)
FCSC : 3.00 (unch)
Agenus (AGEN) Q1 Earnings Beat Estimates, Revenues Miss

Agenus' (AGEN) earnings beat estimates in the first quarter of 2019. Sales marginally miss the same.

GNMSF : 232.5000 (-3.13%)
GILD : 72.66 (-2.73%)
FCSC : 3.00 (unch)
AGEN : 2.67 (-9.49%)
Horizon Therapeutics' (HZNP) Q1 Earnings Beat Estimates

Horizon Therapeutics' (HZNP) sales beat estimates in the first quarter of 2019, primarily owing to strong performance of Krystexxa, Ravicti, Procysbi and Rayos.

HZNP : 34.06 (-3.05%)
GNMSF : 232.5000 (-3.13%)
FCSC : 3.00 (unch)
GILD : 72.66 (-2.73%)
Amicus' (FOLD) Earnings & Revenues Miss Estimates in Q1

Amicus (FOLD) reports wider-than-expected loss in the first quarter of 2019. Also, sales miss estimates.

FCSC : 3.00 (unch)
GILD : 72.66 (-2.73%)
FOLD : 9.34 (-5.18%)
GNMSF : 232.5000 (-3.13%)
AMAG Q1 Loss Wider Than Expected, Revenues Lag Estimates

AMAG (AMAG) reports wider-than-expected loss and misses sales estimates in the first quarter of 2019.

AMAG : 7.54 (-5.51%)
FCSC : 3.00 (unch)
LGND : 103.36 (+0.72%)
GNMSF : 232.5000 (-3.13%)
What's in the Cards for AcelRx (ACRX) This Earnings Season?

We expect AcelRx (ACRX) to provide update on the launch of its newly approved drug DSUVIA, when it reports first-quarter 2019 results.

HZNP : 34.06 (-3.05%)
INO : 4.36 (+9.27%)
GNMSF : 232.5000 (-3.13%)
ACRX : 1.29 (-4.44%)
What's in Cards for Cumberland (CPIX) This Earnings Season?

Cumberland (CPIX) will provide updates on pipeline candidates with the release of its first-quarter 2019 results.

INO : 4.36 (+9.27%)
HZNP : 34.06 (-3.05%)
GNMSF : 232.5000 (-3.13%)
CPIX : 4.10 (-1.44%)
What's in the Cards for Corbus (CRBP) This Earnings Season?

Corbus (CRBP) will provide updates on its lead candidate lenabasum, when it releases first-quarter 2019 results.

INO : 4.36 (+9.27%)
GNMSF : 232.5000 (-3.13%)
HZNP : 34.06 (-3.05%)
CRBP : 4.85 (-8.14%)
Seattle Genetics' Adcetris Progresses Well Amid Competition

Seattle Genetics (SEGN) focuses on improving sales of its flagship product, Adcetris. The drug's label expansion programs also appear encouraging.

MRK : 78.08 (-2.33%)
BMY : 59.58 (-3.97%)
SGEN : 108.31 (-3.39%)
GNMSF : 232.5000 (-3.13%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 88% Buy with a Weakening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Trade GNMSF with:

Key Turning Points

2nd Resistance Point 239.1667
1st Resistance Point 235.8333
Last Price 232.5000
1st Support Level 230.8333
2nd Support Level 229.1667

See More

52-Week High 250.1500
Last Price 232.5000
Fibonacci 61.8% 216.0183
Fibonacci 50% 205.4750
Fibonacci 38.2% 194.9317
52-Week Low 160.8000

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar